Impact of primary platinum-free interval and BRCA1/2 mutation status on treatment and survival in patients with recurrent ovarian cancer
Author:
Funder
AstraZeneca LP
Publisher
Elsevier BV
Subject
Obstetrics and Gynaecology,Oncology
Reference16 articles.
1. Latest research and treatment of advanced-stage epithelial ovarian cancer;Coleman;Nat. Rev. Clin. Oncol.,2013
2. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup;Bookman;J. Clin. Oncol.,2009
3. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin;Markman;J. Clin. Oncol.,1991
4. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds;Gore;Gynecol. Oncol.,1990
5. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity;Gallagher;Ann. Oncol.,2011
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Effective sequential combined therapy with carboplatin and a CDC7 inhibitor in ovarian cancer;Translational Oncology;2024-01
2. Platinum-free Interval May Predict Duration of Maintenance Bevacizumab and Survival in Platinum-sensitive Recurrent Ovarian Cancer;In Vivo;2023-12-25
3. Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial;Clinical Cancer Research;2023-02-17
4. Comparison of treatment outcomes between first-line chemotherapy with or without bevacizumab for advanced ovarian, fallopian tube, and primary peritoneal cancer (Tohoku gynecologic cancer unit: TGCU-RS001 study);International Journal of Clinical Oncology;2022-10-10
5. Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium;Annals of Surgical Oncology;2022-09-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3